Maplirpacept

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a 13-point increase in Likelihood of Approval (LoA) to 50% for obesity. Pfizer's maplirpacept saw its Phase Transition Success Rate (PTSR) drop after a Phase I trial termination. Vaxcyte's VAX-31 pneumonia vaccine and Atsena Therapeutics' ATSN-101 for Leber Congenital Amaurosis (LCA) both reported positive Phase I/II trial results, increasing their PTSR. Les Laboratoires Servier's oncology Phase I trial termination led to a decline in PTSR for S-64315 and S-65487 in non-Hodgkin lymphoma (NHL), acute myeloid leukaemia (AML), and multiple myeloma (MM).

Pipeline Moves: Novo Nordisk's liraglutide scores in Phase III paediatric trial

Related Clinical Trials:

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Pipeline Moves: Novo Nordisk's Saxenda scores in Phase III paediatric trial